Leonhard Paul Unkelbach

Leonhard Paul Unkelbach

Auto-generated profile, based on publicly available information

Leonhard Paul Unkelbach

Department of Internal Medicine I, Cardiology, University Hospital Augsburg, University of Augsburg, Germany (L.P.U., D.B.).

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2025 in Cardiovascular Research
Verified
Journal Article
Closed access
JHJiaying Han
Jiaying Han
CBConor J Bloxham
Conor J Bloxham
KKKilian Kirmes
Kilian Kirmes
GVGiacomo Viggiani
Giacomo Viggiani
LULeonhard P Unkelbach
Leonhard P Unkelbach
DBDario Bongiovanni
Dario Bongiovanni
Initially recognized for their role in vascular haemostasis, platelets are now understood to be critical regulators of inflammation and immune responses through complex interactions with immune cells. Key to this role is the formation of platelet–leukocyte aggregates (PLAs), with platelet–monocyte aggregates (PMAs) representing the most thoroughly studied type in cardiovascular disease. PLAs form through the binding of platelet surface P-selectin to P-selectin glycoprotein ligand on leukocytes, an early interaction that may trigger broader inflammatory cascades. Recent studies link circulating PMAs with in vivo platelet activation and elevated PMA levels in patients with high thrombogenic risk, such as those with diabetes and acute myocardial infarction. Furthermore, PMA levels correlate with disease severity and long-term cardiovascular outcomes, highlighting their potential as prognostic biomarkers for adverse cardiovascular events. Therapeutic strategies, such as antiplatelet agents and P-selectin antagonists, have demonstrated efficacy in the inhibition of PLA formation. However, the development of selective inhibitors that preserve the haemostatic and immune functions of platelets remains an unmet clinical need. Despite significant progress, the precise biological functions and underlying mechanisms of PLAs are not fully understood. This review integrates preclinical and clinical data to provide a comprehensive overview of platelet–leukocyte biology, with a focus on the prognostic role and therapeutic potential of PLAs in cardiovascular disease.

1 August 2025 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Open access
SMStefano Ministrini
Stefano Ministrini
LLLuca Liberale
Luca Liberale
YPYustina M. Puspitasari
Yustina M. Puspitasari
JHJiaying Han
Jiaying Han
KKKilian Kirmes
Kilian Kirmes
GCGiovanni Camici
Giovanni Camici
BACKGROUND: Recent clinical trials demonstrated a reduction in biomarkers of thrombosis and inflammation in patients with very high cardiovascular risk treated with the anti–IL-6 (interleukin 6) monoclonal antibody ziltivekimab. However, if and how direct IL-6 inhibition exerts antithrombotic effects remains unknown. This translational project aimed to investigate the effect of direct IL-6 inhibition on experimental arterial thrombus formation and its underlying cellular mechanisms. METHODS: Three-month-old C57BL/6J male and female mice received very low dose lipopolysaccharide for 4 weeks; in addition to lipopolysaccharide, during the fourth week, mice were randomized to receive either anti-mouse IL-6 monoclonal antibody 200 μg or IgG1 isotype control. Thrombosis of the right common carotid artery was induced by endothelial-targeted laser injury. Coagulation factors and platelet reactivity were assessed in treated mice and controls. Platelets were isolated from whole blood and their reactivity to different chemical stimuli was measured by fluorescence-activated cell sorting. Additionally, whole blood samples from patients with a history of percutaneous coronary intervention were incubated ex vivo with either ziltivekimab biosimilar or IgG1 isotype control. Platelet reactivity at rest and in response to diverse chemical stimuli was quantified by fluorescence-activated cell sorting. RESULTS: Mice with low-grade chronic inflammation treated with anti–IL-6 monoclonal antibody displayed significantly blunted thrombus formation, without any significant difference in coagulation factors. Ex vivo stimulation with Collagen-rP (collagen-related peptide) significantly activated platelets isolated from control mice but not those obtained from mice treated with anti–IL-6 monoclonal antibody. Similarly, platelet reactivity from patients with previous percutaneous coronary intervention fell significantly after ex vivo treatment with ziltivekimab biosimilar. CONCLUSIONS: Direct IL-6 inhibition blunts thrombus formation by reducing collagen-induced platelet activation. These findings offer a potential mechanistic explanation for the results observed in the RESCUE trial and support the rationale of the ongoing ZEUS trial (Ziltivekimab Cardiovascular Outcome Study).